Free Trial
→ Trump Quietly Planning $15 Trillion Crypto Shocker (From Paradigm Press) (Ad) Buy ABBV Stock  Free ABBV Stock Alerts

AbbVie (ABBV) Financials

AbbVie logo
$185.52 +2.26 (+1.23%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$185.58 +0.06 (+0.03%)
As of 04:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for AbbVie

Annual Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 4,278 4,863 11,836 11,542 4,616 7,882 5,687 5,309 5,953 5,144
Consolidated Net Income / (Loss)		 4,286 4,873 11,845 11,549 4,622 7,882 5,687 5,309 5,953 5,144
Net Income / (Loss) Continuing Operations		 4,286 4,873 11,845 11,549 4,622 7,882 5,687 5,309 5,953 5,144
Total Pre-Tax Income 		3,716 6,250 13,477 12,989 3,398 8,426 5,197 7,727 7,884 6,645
Total Operating Income		 9,137 12,757 18,117 17,924 11,363 12,983 6,383 9,545 9,340 7,537
Total Gross Profit		 39,430 33,125 39,943 38,751 29,041 25,827 25,035 21,174 19,806 18,359
Total Revenue		 56,334 54,318 58,054 56,197 45,804 33,266 32,753 28,216 25,638 22,859
Operating Revenue		 56,334 54,318 58,054 56,197 45,804 33,266 32,753 28,216 25,638 22,859
Total Cost of Revenue		 16,904 21,193 18,111 17,446 16,763 7,439 7,718 7,042 5,832 4,500
Operating Cost of Revenue		 16,904 21,193 18,111 17,446 16,763 7,439 7,718 7,042 5,832 4,500
Total Operating Expenses		 30,293 20,368 21,826 20,827 17,678 12,844 18,652 11,629 10,466 10,822
Selling, General & Admin Expense		 17,509 12,872 15,260 13,473 11,299 6,942 7,399 6,295 5,881 6,387
Research & Development Expense		 12,791 7,675 6,510 6,922 6,379 6,792 10,753 5,334 4,585 4,435
Other Operating Expenses / (Income)		 -7.00 -179 56 432 0.00 -890 500 0.00 - -
Total Other Income / (Expense), net		 -5,421 -6,507 -4,640 -4,935 -7,965 -4,557 -1,186 -1,818 -1,456 -892
Interest & Investment Income		 -2,160 -1,684 -2,044 -2,384 -2,280 -1,509 -1,144 -1,004 -965 -686
Other Income / (Expense), net		 -3,261 -4,823 -2,596 -2,551 -5,685 -3,048 -42 -814 -491 -206
Income Tax Expense		 -570 1,377 1,632 1,440 -1,224 544 -490 2,418 1,931 1,501
Net Income / (Loss) Attributable to Noncontrolling Interest		 8.00 10 9.00 7.00 6.00 0.00 0.00 - - -
Basic Earnings per Share		 $2.40 $2.73 $6.65 $6.48 $2.73 $5.30 $3.67 $3.31 $3.65 $3.15
Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.67B 1.48B 1.54B 1.60B 1.62B 1.63B
Diluted Earnings per Share		 $2.39 $2.72 $6.63 $6.45 $2.72 $5.28 $3.66 $3.30 $3.63 $3.13
Weighted Average Diluted Shares Outstanding		 1.77B 1.77B 1.78B 1.78B 1.67B 1.48B 1.55B 1.60B 1.63B 1.64B
Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.48B 1.55B 1.60B 1.63B 1.63B

Quarterly Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -22 1,561 1,370 1,369 822 1,778 2,024 239 2,473 3,949 924
Consolidated Net Income / (Loss)		 -23 1,564 1,373 1,372 824 1,781 2,027 241 2,472 3,952 928
Net Income / (Loss) Continuing Operations		 -23 1,564 1,373 1,372 824 1,781 2,027 241 2,472 3,952 928
Total Pre-Tax Income 		-2,269 2,084 2,146 1,755 1,212 1,953 2,610 475 2,965 4,400 1,183
Total Operating Income		 -1,490 3,831 3,998 2,798 3,195 2,281 4,513 2,768 5,502 4,603 3,295
Total Gross Profit		 11,807 10,248 9,323 8,052 8,035 7,376 9,625 8,089 10,708 9,750 10,144
Total Revenue		 15,102 14,460 14,462 12,310 14,301 13,927 13,865 12,225 15,121 14,812 14,583
Operating Revenue		 15,102 14,460 14,462 12,310 14,301 13,927 13,865 12,225 15,121 14,812 14,583
Total Cost of Revenue		 3,295 4,212 5,139 4,258 6,266 6,551 4,240 4,136 4,413 5,062 4,439
Operating Cost of Revenue		 3,295 4,212 5,139 4,258 6,266 6,551 4,240 4,136 4,413 5,062 4,439
Total Operating Expenses		 13,297 6,417 5,325 5,254 4,840 5,095 5,112 5,321 5,206 5,147 6,849
Selling, General & Admin Expense		 6,530 4,287 3,377 3,315 2,913 3,372 3,548 3,039 3,417 3,304 5,412
Research & Development Expense		 6,774 2,130 1,948 1,939 1,927 1,723 1,733 2,292 1,790 1,614 1,609
Other Operating Expenses / (Income)		 -7.00 0.00 0.00 0.00 - 0.00 -169 -10 -1.00 229 -172
Total Other Income / (Expense), net		 -779 -1,747 -1,852 -1,043 -1,983 -328 -1,903 -2,293 -2,537 -203 -2,112
Interest & Investment Income		 -610 -591 -506 -453 -378 -398 -454 -454 -476 -497 -532
Other Income / (Expense), net		 -169 -1,156 -1,346 -590 -1,605 70 -1,449 -1,839 -2,061 294 -1,580
Income Tax Expense		 -2,246 520 773 383 388 172 583 234 493 448 255
Net Income / (Loss) Attributable to Noncontrolling Interest		 -1.00 3.00 3.00 3.00 2.00 3.00 3.00 2.00 -1.00 3.00 4.00
Basic Earnings per Share		 ($0.02) $0.88 $0.77 $0.77 $0.46 $1.00 $1.14 $0.13 $1.39 $2.22 $0.52
Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Diluted Earnings per Share		 ($0.03) $0.88 $0.77 $0.77 $0.45 $1.00 $1.14 $0.13 $1.40 $2.21 $0.51
Weighted Average Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.78B 1.78B 1.78B 1.78B
Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.76B 1.77B 1.77B 1.77B

Annual Cash Flow Statements for AbbVie

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 -7,290 3,613 -545 1,297 -31,475 32,635 -2,014 4,203 -3,299 51
Net Cash From Operating Activities		 18,806 22,839 24,943 22,777 17,588 13,324 13,427 9,960 7,041 7,535
Net Cash From Continuing Operating Activities		 18,806 22,839 24,943 22,777 17,588 13,324 13,427 9,960 7,041 7,535
Net Income / (Loss) Continuing Operations		 4,286 4,873 11,845 11,549 4,622 7,882 5,687 5,309 5,953 5,144
Consolidated Net Income / (Loss)		 4,286 4,873 11,845 11,549 4,622 7,882 5,687 5,309 5,953 5,144
Depreciation Expense		 764 752 778 803 666 464 471 425 425 417
Amortization Expense		 7,622 7,946 7,689 7,718 5,805 1,553 1,294 1,076 764 419
Non-Cash Adjustments To Reconcile Net Income		 6,594 4,216 3,895 2,157 2,961 1,663 7,052 2,515 1,360 1,051
Changes in Operating Assets and Liabilities, net		 -460 5,052 736 550 3,534 1,762 -1,077 635 -1,461 504
Net Cash From Investing Activities		 -20,820 -2,009 -623 -2,344 -37,557 596 -1,006 -274 -6,074 -12,936
Net Cash From Continuing Investing Activities		 -20,820 -2,009 -623 -2,344 -37,557 596 -1,006 -274 -6,074 -12,936
Purchase of Property, Plant & Equipment		 -974 -777 -695 -787 -798 -552 -638 -529 -479 -532
Acquisitions		 -17,493 0.00 -255 -525 -38,260 0.00 0.00 - -2,495 -11,488
Purchase of Investments		 -3,097 -1,300 -1,977 -1,496 -1,411 -1,718 -2,528 -2,538 -5,577 -1,815
Sale and/or Maturity of Investments		 555 55 1,530 98 1,525 2,699 2,160 2,793 2,359 899
Other Investing Activities, net		 189 13 774 366 1,387 167 0.00 0.00 118 0.00
Net Cash From Financing Activities		 -5,211 -17,222 -24,803 -19,039 -11,501 18,708 -14,396 -5,512 -3,928 5,771
Net Cash From Continuing Financing Activities		 -5,211 -17,222 -24,803 -19,039 -11,501 18,708 -14,396 -5,512 -3,928 5,771
Repayment of Debt		 -14,564 -4,101 -14,403 -9,390 -5,675 -4,501 -6,035 -25 -6,010 -4,018
Repurchase of Common Equity		 -1,807 -2,010 -1,487 -934 -998 -1,053 -12,054 -1,410 -6,102 -7,768
Payment of Dividends		 -11,025 -10,539 -10,043 -9,261 -7,716 -6,366 -5,580 -4,107 -3,717 -3,294
Issuance of Debt		 21,971 0.00 2,000 1,000 3,000 30,783 9,278 44 11,633 20,696
Other Financing Activities, net		 214 -572 -870 -454 -112 -155 -5.00 -14 268 155
Effect of Exchange Rate Changes		 -65 5.00 -62 -97 -5.00 7.00 -39 29 -338 -
Cash Interest Paid		 2,811 2,469 2,546 2,712 2,619 1,794 1,215 1,099 986 536
Cash Income Taxes Paid		 4,064 4,702 2,988 3,648 1,674 1,447 0.00 1,696 3,563 1,108

Quarterly Cash Flow Statements for AbbVie

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Net Change in Cash & Equivalents		 -1,733 -5,873 -4,937 5,253 -473 4,528 2,048 -2,490 -2,631 3,311 2,423
Net Cash From Operating Activities		 7,048 5,447 2,271 4,040 4,753 7,574 6,319 4,193 7,428 7,602 5,005
Net Cash From Continuing Operating Activities		 7,048 5,447 2,271 4,040 4,753 7,574 6,319 4,193 7,428 7,602 5,005
Net Income / (Loss) Continuing Operations		 -23 1,564 1,373 1,372 824 1,781 2,027 241 2,472 3,952 928
Consolidated Net Income / (Loss)		 -23 1,564 1,373 1,372 824 1,781 2,027 241 2,472 3,952 928
Depreciation Expense		 206 191 184 183 187 196 190 179 196 181 203
Amortization Expense		 1,896 1,888 1,947 1,891 1,889 2,039 2,070 1,948 1,961 2,024 1,849
Non-Cash Adjustments To Reconcile Net Income		 5,854 -25 689 76 1,105 1,786 294 1,031 355 781 2,180
Changes in Operating Assets and Liabilities, net		 -885 1,829 -1,922 518 748 1,772 1,738 794 2,444 664 -155
Net Cash From Investing Activities		 -1,874 -8,256 -1,102 -9,588 -800 -369 -341 -499 -448 1,286 130
Net Cash From Continuing Investing Activities		 -1,874 -8,256 -1,102 -9,588 -800 -369 -341 -499 -448 1,286 130
Purchase of Property, Plant & Equipment		 -291 -249 -241 -193 -205 -219 -178 -175 -213 -177 -143
Purchase of Investments		 -1,819 -223 -859 -196 -587 -165 -176 -372 -55 -117 -214
Sale and/or Maturity of Investments		 39 507 3.00 6.00 14 5.00 14 22 70 1,410 42
Other Investing Activities, net		 197 3.00 -5.00 -6.00 -22 10 -1.00 26 5.00 170 445
Net Cash From Financing Activities		 -6,861 -3,072 -6,097 10,819 -4,449 -2,661 -3,920 -6,192 -9,634 -5,518 -2,679
Net Cash From Continuing Financing Activities		 -6,861 -3,072 -6,097 10,819 -4,449 -2,661 -3,920 -6,192 -9,634 -5,518 -2,679
Repayment of Debt		 -5,662 -371 -3,348 -5,183 -1,796 28 -1,003 -1,330 -6,862 -2,686 3.00
Repurchase of Common Equity		 -457 -17 -9.00 -1,324 -41 -4.00 -10 -1,955 -4.00 -4.00 -9.00
Payment of Dividends		 -2,752 -2,751 -2,750 -2,772 -2,626 -2,627 -2,625 -2,661 -2,506 -2,504 -2,507
Issuance of Debt		 2,000 - - 19,971 - - - 0.00 - - -
Other Financing Activities, net		 10 67 10 127 14 -58 -282 -246 -262 -324 -166
Effect of Exchange Rate Changes		 -46 8.00 -9.00 -18 23 -16 -10 8.00 23 -59 -33

Annual Balance Sheets for AbbVie

This table presents AbbVie's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 135,161 134,711 138,805 146,529 150,565 89,115 59,352 70,786 66,099 53,050
Total Current Assets		 25,582 33,002 28,463 27,928 24,173 49,519 16,945 21,223 16,187 16,314
Cash & Equivalents		 5,524 12,814 9,201 9,746 8,449 39,924 7,289 9,303 5,100 8,399
Short-Term Investments		 31 2.00 28 84 30 0.00 772 486 1,323 8.00
Accounts Receivable		 10,919 11,155 11,254 9,977 8,822 5,428 5,384 5,088 4,758 4,730
Inventories, net		 4,181 4,099 3,579 3,128 3,310 1,813 1,605 1,605 1,444 1,719
Prepaid Expenses		 4,927 4,932 4,401 4,993 3,562 2,354 1,895 4,741 3,562 1,458
Plant, Property, & Equipment, net		 5,134 4,989 4,935 5,110 5,248 2,962 2,883 2,803 2,604 2,565
Total Noncurrent Assets		 104,445 96,720 105,407 113,491 121,144 36,634 39,524 46,760 47,308 34,171
Long-Term Investments		 279 304 241 277 293 93 1,420 2,090 1,783 145
Goodwill		 34,956 32,293 32,156 32,379 33,124 15,604 15,663 15,785 15,416 13,168
Intangible Assets		 60,068 55,610 67,439 75,951 82,876 18,649 21,233 27,559 28,897 19,709
Other Noncurrent Operating Assets		 9,142 8,513 5,571 4,884 4,851 2,288 1,208 1,326 1,212 1,149
Total Liabilities & Shareholders' Equity		 135,161 134,711 138,805 146,529 150,565 89,115 59,352 70,786 66,099 53,050
Total Liabilities		 131,797 124,314 121,518 131,093 137,468 97,287 67,798 65,689 61,463 49,105
Total Current Liabilities		 38,749 37,841 29,538 35,194 28,661 15,585 17,239 16,641 9,781 10,894
Short-Term Debt		 6,804 7,191 4,136 12,495 8,502 3,753 5,308 6,415 402 2,431
Accounts Payable		 31,945 30,650 25,402 22,699 20,159 11,832 11,931 10,226 9,379 8,463
Total Noncurrent Liabilities		 93,048 86,473 91,980 95,899 108,807 81,702 50,559 49,048 51,682 38,211
Long-Term Debt		 60,340 52,194 59,135 64,189 77,554 62,975 49,492 46,558 44,792 32,935
Noncurrent Deferred & Payable Income Tax Liabilities		 2,579 1,952 2,190 3,009 3,646 1,130 1,067 2,490 6,890 5,276
Other Noncurrent Operating Liabilities		 30,129 32,327 30,655 28,701 27,607 17,597 - - - -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,364 10,397 17,287 15,436 13,097 -8,172 -8,446 5,097 4,636 3,945
Total Preferred & Common Equity		 3,325 10,360 17,254 15,408 13,076 -8,172 -8,446 5,097 4,636 3,945
Total Common Equity		 3,325 10,360 17,254 15,408 13,076 -8,172 -8,446 5,097 4,636 3,945
Common Stock		 21,351 20,198 19,263 18,323 17,402 15,211 14,774 14,288 13,696 13,097
Retained Earnings		 -7,900 -1,000 4,784 3,127 1,055 4,717 3,368 5,459 4,378 2,248
Treasury Stock		 -8,201 -6,533 -4,594 -3,143 -2,264 -24,504 -24,108 -11,923 -10,852 -8,839
Accumulated Other Comprehensive Income / (Loss)		 -1,925 -2,305 -2,199 -2,899 -3,117 -3,596 -2,480 -2,727 -2,586 -2,561
Noncontrolling Interest		 39 37 33 28 21 0.00 - - - -

Quarterly Balance Sheets for AbbVie

This table presents AbbVie's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Total Assets		 135,161 143,422 141,937 148,874 134,711 136,221 135,367 134,544 138,805 141,325 143,186
Total Current Assets		 25,582 27,785 33,816 38,871 33,002 33,224 28,852 26,488 28,463 30,364 29,100
Cash & Equivalents		 5,524 7,257 13,130 18,067 12,814 13,287 8,759 6,711 9,201 11,832 8,521
Short-Term Investments		 31 28 27 2.00 2.00 3.00 7.00 11 28 47 1,440
Accounts Receivable		 10,919 11,472 11,724 11,949 11,155 11,412 11,491 11,473 11,254 10,743 11,237
Inventories, net		 4,181 4,450 4,218 4,245 4,099 3,981 4,055 3,833 3,579 3,172 3,396
Prepaid Expenses		 4,927 4,578 4,717 4,608 4,932 4,541 4,540 4,460 4,401 4,570 4,506
Plant, Property, & Equipment, net		 5,134 5,141 5,023 4,980 4,989 4,934 4,943 4,931 4,935 4,893 4,958
Total Noncurrent Assets		 104,445 110,496 103,098 105,023 96,720 98,063 101,572 103,125 105,407 106,068 109,128
Long-Term Investments		 279 267 272 305 304 275 288 257 241 235 244
Goodwill		 34,956 35,295 33,386 33,426 32,293 32,091 32,224 32,220 32,156 31,726 32,028
Intangible Assets		 60,068 66,646 60,243 62,225 55,610 58,603 62,862 64,848 67,439 68,725 71,823
Other Noncurrent Operating Assets		 9,142 8,288 9,197 9,067 8,513 7,094 6,198 5,800 5,571 5,382 5,033
Total Liabilities & Shareholders' Equity		 135,161 143,422 141,937 148,874 134,711 136,221 135,367 134,544 138,805 141,325 143,186
Total Liabilities		 131,797 137,351 135,116 140,827 124,314 124,092 122,469 121,241 121,518 125,298 128,498
Total Current Liabilities		 38,749 43,062 41,915 41,522 37,841 34,773 32,239 27,590 29,538 32,712 34,473
Short-Term Debt		 6,804 12,570 12,586 10,196 7,191 5,115 5,203 2,801 4,136 9,207 11,930
Accounts Payable		 31,945 30,492 29,329 31,326 30,650 29,658 27,036 24,789 25,402 23,505 22,543
Total Noncurrent Liabilities		 93,048 94,289 93,201 99,305 86,473 89,319 90,230 93,651 91,980 92,586 94,025
Long-Term Debt		 60,340 58,509 58,048 63,805 52,194 55,631 55,812 59,292 59,135 60,399 61,002
Noncurrent Deferred & Payable Income Tax Liabilities		 2,579 2,749 2,726 2,722 1,952 2,044 2,124 2,110 2,190 1,972 2,255
Other Noncurrent Operating Liabilities		 30,129 33,031 32,427 32,778 32,327 31,644 32,294 32,249 30,655 30,215 30,768
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,364 6,071 6,821 8,047 10,397 12,129 12,898 13,303 17,287 16,027 14,688
Total Preferred & Common Equity		 3,325 6,032 6,778 8,007 10,360 12,094 12,866 13,274 17,254 15,994 14,653
Total Common Equity		 3,325 6,032 6,778 8,007 10,360 12,094 12,866 13,274 17,254 15,994 14,653
Common Stock		 21,351 21,178 20,897 20,674 20,198 20,039 19,857 19,637 19,263 19,074 18,924
Retained Earnings		 -7,900 -4,964 -3,768 -2,384 -1,000 933 1,789 2,393 4,784 4,953 3,516
Treasury Stock		 -8,201 -7,848 -7,838 -7,829 -6,533 -6,525 -6,528 -6,524 -4,594 -4,590 -4,591
Accumulated Other Comprehensive Income / (Loss)		 -1,925 -2,334 -2,513 -2,454 -2,305 -2,353 -2,252 -2,232 -2,199 -3,443 -3,196
Noncontrolling Interest		 39 39 43 40 37 35 32 29 33 33 35

Annual Metrics And Ratios for AbbVie

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 3.71% -6.44% 3.30% 22.69% 37.69% 1.57% 16.08% 10.06% 12.16% 14.52%
EBITDA Growth		 -14.25% -30.67% 0.39% 96.67% 1.65% 47.45% -20.78% 1.93% 22.91% 130.32%
EBIT Growth		 -25.94% -48.88% 0.96% 170.75% -42.85% 56.68% -27.37% -1.33% 20.71% 165.62%
NOPAT Growth		 5.95% -37.54% -0.09% 3.11% 27.27% 73.87% 6.51% -7.01% 20.87% 128.42%
Net Income Growth		 -12.05% -58.86% 2.56% 149.87% -41.36% 38.60% 7.12% -10.82% 15.73% 189.97%
EPS Growth		 -12.13% -58.97% 2.79% 137.13% -48.48% 44.26% 10.91% -9.09% 15.97% 184.55%
Operating Cash Flow Growth		 -17.66% -8.44% 9.51% 29.50% 32.00% -0.77% 34.81% 41.46% -6.56% 324.51%
Free Cash Flow Firm Growth		 -89.63% -9.22% 10.46% 143.10% -285.00% 86.95% 718.79% 152.22% 70.65% -486.93%
Invested Capital Growth		 14.14% -20.29% -13.32% -9.26% 387.52% -49.72% -20.17% 10.97% 35.32% 157.74%
Revenue Q/Q Growth		 1.44% -1.49% 0.41% 1.86% 12.68% 1.21% 1.76% 3.46% 1.57% 4.33%
EBITDA Q/Q Growth		 -18.43% -10.41% -4.85% 30.93% -19.07% 89.65% -29.71% -7.27% 2.37% 61.15%
EBIT Q/Q Growth		 -35.61% -18.92% -8.28% 59.44% -43.76% 128.29% -35.56% -8.81% 1.90% 70.49%
NOPAT Q/Q Growth		 6.90% -18.97% -0.83% -8.22% 44.38% 68.77% -23.71% -16.48% -0.86% 52.33%
Net Income Q/Q Growth		 -16.50% -25.27% -11.72% 53.13% -37.41% 142.15% -24.82% -20.14% -2.07% 82.61%
EPS Q/Q Growth		 -16.72% -25.89% -11.48% 58.87% -42.49% 0.00% 0.00% -19.71% -2.16% 84.12%
Operating Cash Flow Q/Q Growth		 13.90% -10.48% 10.42% 0.98% 9.86% -0.87% 6.40% 11.70% -5.65% 27.73%
Free Cash Flow Firm Q/Q Growth		 687.62% -7.97% 10.42% -18.28% -17.32% 104.98% 102.47% -75.09% -8.45% 18.52%
Invested Capital Q/Q Growth		 -7.07% -4.46% -3.31% 0.29% -4.01% -47.61% -14.37% 10.09% -1.12% -2.25%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 69.99% 60.98% 68.80% 68.96% 63.40% 77.64% 76.44% 75.04% 77.25% 80.31%
EBITDA Margin		 25.32% 30.62% 41.32% 42.52% 26.52% 35.93% 24.75% 36.26% 39.15% 35.73%
Operating Margin		 16.22% 23.49% 31.21% 31.89% 24.81% 39.03% 19.49% 33.83% 36.43% 32.97%
EBIT Margin		 10.43% 14.61% 26.74% 27.36% 12.40% 29.87% 19.36% 30.94% 34.52% 32.07%
Profit (Net Income) Margin		 7.61% 8.97% 20.40% 20.55% 10.09% 23.69% 17.36% 18.82% 23.22% 22.50%
Tax Burden Percent		 115.34% 77.97% 87.89% 88.91% 136.02% 93.54% 109.43% 68.71% 75.51% 77.41%
Interest Burden Percent		 63.24% 78.77% 86.83% 84.49% 59.85% 84.81% 81.96% 88.50% 89.09% 90.64%
Effective Tax Rate		 -15.34% 22.03% 12.11% 11.09% -36.02% 6.46% -9.43% 31.29% 24.49% 22.59%
Return on Invested Capital (ROIC)		 17.37% 15.57% 20.80% 18.49% 28.38% 43.83% 16.82% 14.94% 19.49% 27.33%
ROIC Less NNEP Spread (ROIC-NNEP)		 5.75% 5.43% 14.03% 12.39% 7.54% 32.00% 13.81% 11.74% 16.04% 23.60%
Return on Net Nonoperating Assets (RNNOA)		 44.92% 19.63% 51.59% 62.46% 159.31% -138.70% -356.44% 94.16% 119.26% 153.57%
Return on Equity (ROE)		 62.29% 35.20% 72.40% 80.95% 187.70% -94.86% -339.62% 109.09% 138.75% 180.90%
Cash Return on Invested Capital (CROIC)		 4.16% 38.16% 35.07% 28.20% -103.54% 110.01% 39.25% 4.53% -10.53% -60.86%
Operating Return on Assets (OROA)		 4.35% 5.80% 10.88% 10.35% 4.74% 13.38% 9.75% 12.76% 14.85% 18.20%
Return on Assets (ROA)		 3.18% 3.56% 8.30% 7.77% 3.86% 10.62% 8.74% 7.76% 9.99% 12.77%
Return on Common Equity (ROCE)		 61.95% 35.12% 72.26% 80.81% 186.90% -94.86% -339.62% 109.09% 138.75% 180.90%
Return on Equity Simple (ROE_SIMPLE)		 128.90% 47.04% 68.65% 74.95% 35.35% -96.45% -67.33% 104.16% 128.41% 130.39%
Net Operating Profit after Tax (NOPAT)		 10,539 9,946 15,923 15,937 15,456 12,145 6,985 6,558 7,052 5,835
NOPAT Margin		 18.71% 18.31% 27.43% 28.36% 33.74% 36.51% 21.33% 23.24% 27.51% 25.52%
Net Nonoperating Expense Percent (NNEP)		 11.62% 10.14% 6.78% 6.10% 20.84% 11.84% 3.00% 3.20% 3.45% 3.73%
Return On Investment Capital (ROIC_SIMPLE)		 14.95% 14.25% 19.77% - - - - - - -
Cost of Revenue to Revenue		 30.01% 39.02% 31.20% 31.04% 36.60% 22.36% 23.56% 24.96% 22.75% 19.69%
SG&A Expenses to Revenue		 31.08% 23.70% 26.29% 23.97% 24.67% 20.87% 22.59% 22.31% 22.94% 27.94%
R&D to Revenue		 22.71% 14.13% 11.21% 12.32% 13.93% 20.42% 32.83% 18.90% 17.88% 19.40%
Operating Expenses to Revenue		 53.77% 37.50% 37.60% 37.06% 38.59% 38.61% 56.95% 41.21% 40.82% 47.34%
Earnings before Interest and Taxes (EBIT)		 5,876 7,934 15,521 15,373 5,678 9,935 6,341 8,731 8,849 7,331
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 14,262 16,632 23,988 23,894 12,149 11,952 8,106 10,232 10,038 8,167
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 93.56 25.24 15.22 13.98 12.42 0.00 0.00 22.45 15.69 16.90
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 5.52 4.81 4.52 3.83 3.55 3.20 3.26 4.05 2.84 2.92
Price to Earnings (P/E)		 72.72 53.77 22.18 18.66 35.18 13.51 18.77 21.55 12.22 12.96
Dividend Yield		 3.52% 4.00% 3.80% 4.27% 5.13% 5.94% 5.06% 3.57% 5.09% 4.95%
Earnings Yield		 1.38% 1.86% 4.51% 5.36% 2.84% 7.40% 5.33% 4.64% 8.18% 7.72%
Enterprise Value to Invested Capital (EV/IC)		 5.76 5.43 4.45 3.44 2.65 7.19 4.12 3.37 2.64 3.04
Enterprise Value to Revenue (EV/Rev)		 6.61 5.67 5.45 5.02 5.23 4.00 4.64 5.51 4.28 4.09
Enterprise Value to EBITDA (EV/EBITDA)		 26.11 18.51 13.19 11.80 19.73 11.15 18.76 15.20 10.93 11.45
Enterprise Value to EBIT (EV/EBIT)		 63.38 38.79 20.38 18.34 42.22 13.41 23.98 17.81 12.40 12.75
Enterprise Value to NOPAT (EV/NOPAT)		 35.34 30.95 19.87 17.69 15.51 10.97 21.77 23.71 15.56 16.02
Enterprise Value to Operating Cash Flow (EV/OCF)		 19.80 13.48 12.68 12.38 13.63 10.00 11.33 15.61 15.59 12.41
Enterprise Value to Free Cash Flow (EV/FCFF)		 147.41 12.63 11.78 11.60 0.00 4.37 9.33 78.10 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 19.96 5.71 3.66 4.97 6.57 -8.17 -6.49 10.39 9.75 8.96
Long-Term Debt to Equity		 17.94 5.02 3.42 4.16 5.92 -7.71 -5.86 9.13 9.66 8.35
Financial Leverage		 7.82 3.61 3.68 5.04 21.12 -4.33 -25.80 8.02 7.44 6.51
Leverage Ratio		 19.61 9.88 8.72 10.41 48.67 -8.93 -38.86 14.06 13.89 14.17
Compound Leverage Factor		 12.40 7.78 7.57 8.80 29.12 -7.58 -31.85 12.45 12.37 12.84
Debt to Total Capital		 95.23% 85.10% 78.54% 83.24% 86.79% 113.96% 118.22% 91.22% 90.70% 89.96%
Short-Term Debt to Total Capital		 9.65% 10.30% 5.13% 13.56% 8.57% 6.41% 11.45% 11.05% 0.81% 6.18%
Long-Term Debt to Total Capital		 85.58% 74.80% 73.41% 69.68% 78.22% 107.55% 106.77% 80.18% 89.89% 83.78%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.06% 0.05% 0.04% 0.03% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 4.72% 14.85% 21.42% 16.73% 13.19% -13.96% -18.22% 8.78% 9.30% 10.04%
Debt to EBITDA		 4.71 3.57 2.64 3.21 7.08 5.58 6.76 5.18 4.50 4.33
Net Debt to EBITDA		 4.30 2.78 2.24 2.79 6.36 2.23 5.59 4.02 3.68 3.28
Long-Term Debt to EBITDA		 4.23 3.14 2.47 2.69 6.38 5.27 6.11 4.55 4.46 4.03
Debt to NOPAT		 6.37 5.97 3.97 4.81 5.57 5.49 7.85 8.08 6.41 6.06
Net Debt to NOPAT		 5.82 4.65 3.38 4.18 5.00 2.20 6.49 6.27 5.24 4.60
Long-Term Debt to NOPAT		 5.73 5.25 3.71 4.03 5.02 5.19 7.09 7.10 6.35 5.64
Altman Z-Score		 1.78 1.81 2.12 1.69 1.11 1.93 1.92 2.04 1.75 1.88
Noncontrolling Interest Sharing Ratio		 0.55% 0.25% 0.19% 0.17% 0.43% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.66 0.87 0.96 0.79 0.84 3.18 0.98 1.28 1.65 1.50
Quick Ratio		 0.43 0.63 0.69 0.56 0.60 2.91 0.78 0.89 1.14 1.21
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 2,527 24,372 26,848 24,305 -56,386 30,479 16,303 1,991 -3,813 -12,990
Operating Cash Flow to CapEx		 1,930.80% 2,939.38% 3,588.92% 2,894.16% 2,204.01% 2,413.77% 2,104.55% 1,882.80% 1,469.94% 1,416.35%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.42 0.40 0.41 0.38 0.38 0.45 0.50 0.41 0.43 0.57
Accounts Receivable Turnover		 5.10 4.85 5.47 5.98 6.43 6.15 6.26 5.73 5.40 5.40
Inventory Turnover		 4.08 5.52 5.40 5.42 6.54 4.35 4.81 4.62 3.69 3.17
Fixed Asset Turnover		 11.13 10.95 11.56 10.85 11.16 11.38 11.52 10.44 9.92 9.05
Accounts Payable Turnover		 0.54 0.76 0.75 0.81 1.05 0.63 0.70 0.72 0.65 0.58
Days Sales Outstanding (DSO)		 71.51 75.29 66.74 61.05 56.78 59.32 58.35 63.68 67.54 67.58
Days Inventory Outstanding (DIO)		 89.39 66.12 67.58 67.35 55.77 83.85 75.90 79.02 98.98 115.30
Days Payable Outstanding (DPO)		 675.79 482.68 484.70 448.33 348.29 582.97 523.92 508.08 558.33 625.25
Cash Conversion Cycle (CCC)		 -514.89 -341.27 -350.37 -319.93 -235.74 -439.81 -389.67 -365.38 -391.81 -442.36
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 64,674 56,662 71,088 82,013 90,381 18,539 36,873 46,191 41,624 30,759
Invested Capital Turnover		 0.93 0.85 0.76 0.65 0.84 1.20 0.79 0.64 0.71 1.07
Increase / (Decrease) in Invested Capital		 8,012 -14,426 -10,925 -8,368 71,842 -18,334 -9,318 4,567 10,865 18,825
Enterprise Value (EV)		 372,436 307,792 316,377 281,950 239,699 133,216 152,086 155,500 109,742 93,473
Market Capitalization		 311,087 261,490 262,543 215,345 162,394 106,505 106,767 114,406 72,754 66,659
Book Value per Share		 $1.88 $5.87 $9.76 $8.72 $7.41 ($5.53) ($5.61) $3.19 $2.85 $2.41
Tangible Book Value per Share		 ($51.89) ($43.92) ($46.56) ($52.56) ($58.30) ($28.69) ($30.14) ($23.96) ($24.42) ($17.70)
Total Capital		 70,508 69,782 80,558 92,120 99,153 58,556 46,354 58,070 49,830 39,311
Total Debt		 67,144 59,385 63,271 76,684 86,056 66,728 54,800 52,973 45,194 35,366
Total Long-Term Debt		 60,340 52,194 59,135 64,189 77,554 62,975 49,492 46,558 44,792 32,935
Net Debt		 61,310 46,265 53,801 66,577 77,284 26,711 45,319 41,094 36,988 26,814
Capital Expenditures (CapEx)		 974 777 695 787 798 552 638 529 479 532
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11,918 -10,464 -6,168 -4,601 -4,465 -2,237 -3,047 1,208 385 -556
Debt-free Net Working Capital (DFNWC)		 -6,363 2,352 3,061 5,229 4,014 37,687 5,014 10,997 6,808 7,851
Net Working Capital (NWC)		 -13,167 -4,839 -1,075 -7,266 -4,488 33,934 -294 4,582 6,406 5,420
Net Nonoperating Expense (NNE)		 6,253 5,073 4,078 4,388 10,834 4,263 1,298 1,249 1,099 691
Net Nonoperating Obligations (NNO)		 61,310 46,265 53,801 66,577 77,284 26,711 45,319 41,094 36,988 26,814
Total Depreciation and Amortization (D&A)		 8,386 8,698 8,467 8,521 6,471 2,017 1,765 1,501 1,189 836
Debt-free, Cash-free Net Working Capital to Revenue		 -21.16% -19.26% -10.62% -8.19% -9.75% -6.72% -9.30% 4.28% 1.50% -2.43%
Debt-free Net Working Capital to Revenue		 -11.30% 4.33% 5.27% 9.30% 8.76% 113.29% 15.31% 38.97% 26.55% 34.35%
Net Working Capital to Revenue		 -23.37% -8.91% -1.85% -12.93% -9.80% 102.01% -0.90% 16.24% 24.99% 23.71%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.40 $2.73 $6.65 $6.48 $2.73 $5.30 $3.67 $3.31 $3.65 $3.15
Adjusted Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.67B 1.48B 1.54B 1.60B 1.62B 1.63B
Adjusted Diluted Earnings per Share		 $2.39 $2.72 $6.63 $6.45 $2.72 $5.28 $3.66 $3.30 $3.63 $3.13
Adjusted Weighted Average Diluted Shares Outstanding		 1.77B 1.77B 1.78B 1.78B 1.67B 1.48B 1.55B 1.60B 1.63B 1.64B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.48B 1.48B 1.59B 1.59B 1.61B
Normalized Net Operating Profit after Tax (NOPAT)		 6,396 9,946 15,923 15,937 7,954 12,145 4,468 6,558 7,052 5,835
Normalized NOPAT Margin		 11.35% 18.31% 27.43% 28.36% 17.37% 36.51% 13.64% 23.24% 27.51% 25.52%
Pre Tax Income Margin		 6.60% 11.51% 23.21% 23.11% 7.42% 25.33% 15.87% 27.39% 30.75% 29.07%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 257.23% 216.27% 84.79% 80.19% 166.94% 80.77% 98.12% 77.36% 62.44% 64.04%
Augmented Payout Ratio		 299.39% 257.52% 97.34% 88.28% 188.53% 94.13% 310.08% 103.92% 164.94% 215.05%

Quarterly Metrics And Ratios for AbbVie

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 5.60% 3.83% 4.31% 0.70% -5.42% -5.97% -4.92% -9.70% 1.58% 3.28% 4.47%
EBITDA Growth		 -87.92% 3.66% -10.16% 40.12% -34.51% -35.43% 41.33% -59.37% -17.93% 10.97% -5.09%
EBIT Growth		 -204.34% 13.78% -13.45% 137.67% -53.79% -51.99% 78.66% -83.01% -28.93% 14.60% -3.05%
NOPAT Growth		 -148.02% 38.22% -27.02% 55.75% -52.65% -49.69% 35.60% -67.34% -4.54% 11.35% -11.98%
Net Income Growth		 -102.79% -12.18% -32.26% 469.29% -66.67% -54.93% 118.43% -94.64% -38.89% 24.28% 20.68%
EPS Growth		 -106.67% -12.00% -32.46% 492.31% -67.86% -54.75% 123.53% -94.82% -38.05% 24.16% 21.43%
Operating Cash Flow Growth		 48.29% -28.08% -64.06% -3.65% -36.01% -0.37% 26.25% -14.57% 46.36% -4.20% 2.35%
Free Cash Flow Firm Growth		 -154.55% -145.51% -78.89% -53.62% 7.00% 31.45% 45.54% 29.66% 17.75% -22.97% -14.91%
Invested Capital Growth		 14.14% 17.35% -1.28% -6.93% -20.29% -19.33% -16.22% -16.52% -13.32% -10.10% -9.84%
Revenue Q/Q Growth		 4.44% -0.01% 17.48% -13.92% 2.69% 0.45% 13.42% -19.15% 2.09% 1.57% 7.72%
EBITDA Q/Q Growth		 -90.68% -0.61% 11.70% 16.80% -20.06% -13.86% 74.21% -45.41% -21.18% 88.53% -49.91%
EBIT Q/Q Growth		 -162.02% 0.87% 20.11% 38.87% -32.37% -23.27% 229.82% -73.00% -29.73% 185.54% -68.64%
NOPAT Q/Q Growth		 -136.28% 12.40% 16.94% 0.70% 4.43% -40.65% 149.57% -69.38% 10.95% 59.95% -39.89%
Net Income Q/Q Growth		 -101.47% 13.91% 0.07% 66.50% -53.73% -12.14% 741.08% -90.25% -37.45% 325.86% -79.35%
EPS Q/Q Growth		 -103.41% 14.29% 0.00% 71.11% -55.00% -12.28% 776.92% -90.71% -36.65% 333.33% -79.68%
Operating Cash Flow Q/Q Growth		 29.39% 139.85% -43.79% -15.00% -37.25% 19.86% 50.70% -43.55% -2.29% 51.89% 1.98%
Free Cash Flow Firm Q/Q Growth		 -22.15% -318.61% -51.07% -58.25% 1.90% 1.42% 7.48% -3.67% 25.18% 12.29% -4.24%
Invested Capital Q/Q Growth		 -7.07% 8.70% 0.55% 12.38% -4.46% -8.56% -5.20% -3.76% -3.31% -5.03% -5.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 78.18% 70.87% 64.47% 65.41% 56.18% 52.96% 69.42% 66.17% 70.82% 65.83% 69.56%
EBITDA Margin		 2.93% 32.88% 33.07% 34.78% 25.63% 32.93% 38.40% 25.00% 37.02% 47.95% 25.83%
Operating Margin		 -9.87% 26.49% 27.64% 22.73% 22.34% 16.38% 32.55% 22.64% 36.39% 31.08% 22.59%
EBIT Margin		 -10.99% 18.50% 18.34% 17.94% 11.12% 16.88% 22.10% 7.60% 22.76% 33.06% 11.76%
Profit (Net Income) Margin		 -0.15% 10.82% 9.49% 11.15% 5.76% 12.79% 14.62% 1.97% 16.35% 26.68% 6.36%
Tax Burden Percent		 1.01% 75.05% 63.98% 78.18% 67.99% 91.19% 77.66% 50.74% 83.37% 89.82% 78.44%
Interest Burden Percent		 136.77% 77.91% 80.92% 79.48% 76.23% 83.07% 85.18% 51.13% 86.17% 89.85% 68.98%
Effective Tax Rate		 0.00% 24.95% 36.02% 21.82% 32.01% 8.81% 22.34% 49.26% 16.63% 10.18% 21.56%
Return on Invested Capital (ROIC)		 -6.41% 17.13% 15.10% 14.64% 12.92% 12.40% 19.91% 8.67% 23.01% 20.78% 12.45%
ROIC Less NNEP Spread (ROIC-NNEP)		 -4.52% 14.76% 12.92% 13.16% 10.22% 11.83% 17.33% 6.74% 19.49% 20.49% 10.01%
Return on Net Nonoperating Assets (RNNOA)		 -35.31% 89.80% 71.55% 68.28% 36.95% 43.97% 72.05% 27.49% 71.71% 87.01% 49.92%
Return on Equity (ROE)		 -41.72% 106.93% 86.65% 82.92% 49.86% 56.37% 91.96% 36.16% 94.71% 107.80% 62.37%
Cash Return on Invested Capital (CROIC)		 4.16% -0.67% 15.71% 22.62% 38.16% 39.88% 37.98% 36.10% 35.07% 31.31% 29.50%
Operating Return on Assets (OROA)		 -4.59% 7.35% 7.27% 6.89% 4.42% 6.71% 8.89% 3.10% 9.26% 13.17% 4.63%
Return on Assets (ROA)		 -0.06% 4.30% 3.77% 4.28% 2.29% 5.08% 5.88% 0.81% 6.65% 10.63% 2.51%
Return on Common Equity (ROCE)		 -41.49% 106.49% 86.32% 82.65% 49.74% 56.24% 91.74% 36.09% 94.54% 107.58% 62.23%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 85.10% 78.93% 74.98% 0.00% 53.92% 67.56% 57.20% 0.00% 83.89% 86.30%
Net Operating Profit after Tax (NOPAT)		 -1,043 2,875 2,558 2,187 2,172 2,080 3,505 1,404 4,587 4,134 2,585
NOPAT Margin		 -6.91% 19.88% 17.69% 17.77% 15.19% 14.94% 25.28% 11.49% 30.34% 27.91% 17.72%
Net Nonoperating Expense Percent (NNEP)		 -1.90% 2.37% 2.17% 1.47% 2.69% 0.57% 2.58% 1.93% 3.51% 0.29% 2.44%
Return On Investment Capital (ROIC_SIMPLE)		 -1.48% - - - 3.11% - - - 5.69% - -
Cost of Revenue to Revenue		 21.82% 29.13% 35.53% 34.59% 43.82% 47.04% 30.58% 33.83% 29.18% 34.18% 30.44%
SG&A Expenses to Revenue		 43.24% 29.65% 23.35% 26.93% 20.37% 24.21% 25.59% 24.86% 22.60% 22.31% 37.11%
R&D to Revenue		 44.86% 14.73% 13.47% 15.75% 13.47% 12.37% 12.50% 18.75% 11.84% 10.90% 11.03%
Operating Expenses to Revenue		 88.05% 44.38% 36.82% 42.68% 33.84% 36.58% 36.87% 43.53% 34.43% 34.75% 46.97%
Earnings before Interest and Taxes (EBIT)		 -1,659 2,675 2,652 2,208 1,590 2,351 3,064 929 3,441 4,897 1,715
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 443 4,754 4,783 4,282 3,666 4,586 5,324 3,056 5,598 7,102 3,767
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 93.56 57.37 44.28 39.42 25.24 20.78 17.59 20.04 15.22 13.73 16.93
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 5.52 6.23 5.46 5.80 4.81 4.56 4.04 4.69 4.52 3.80 4.33
Price to Earnings (P/E)		 72.72 67.56 56.21 52.67 53.77 38.58 26.06 35.08 22.18 16.38 19.63
Dividend Yield		 3.52% 3.13% 3.57% 3.35% 4.00% 4.11% 4.51% 3.80% 3.80% 4.45% 3.86%
Earnings Yield		 1.38% 1.48% 1.78% 1.90% 1.86% 2.59% 3.84% 2.85% 4.51% 6.11% 5.09%
Enterprise Value to Invested Capital (EV/IC)		 5.76 5.89 5.58 5.83 5.43 5.03 4.29 4.70 4.45 3.77 4.02
Enterprise Value to Revenue (EV/Rev)		 6.61 7.38 6.50 6.82 5.67 5.41 4.97 5.66 5.45 4.79 5.42
Enterprise Value to EBITDA (EV/EBITDA)		 26.11 23.43 20.64 20.79 18.51 16.08 13.20 16.45 13.19 10.99 12.68
Enterprise Value to EBIT (EV/EBIT)		 63.38 44.89 40.61 40.30 38.79 30.51 22.57 29.25 20.38 16.37 19.07
Enterprise Value to NOPAT (EV/NOPAT)		 35.34 41.55 38.46 36.42 30.95 24.32 19.25 23.61 19.87 17.26 19.89
Enterprise Value to Operating Cash Flow (EV/OCF)		 19.80 24.81 19.17 16.37 13.48 11.70 10.90 13.26 12.68 12.27 13.56
Enterprise Value to Free Cash Flow (EV/FCFF)		 147.41 0.00 35.30 24.85 12.63 11.27 10.30 11.83 11.78 11.40 12.91
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 19.96 11.71 10.36 9.20 5.71 5.01 4.73 4.67 3.66 4.34 4.97
Long-Term Debt to Equity		 17.94 9.64 8.51 7.93 5.02 4.59 4.33 4.46 3.42 3.77 4.15
Financial Leverage		 7.82 6.08 5.54 5.19 3.61 3.72 4.16 4.08 3.68 4.25 4.98
Leverage Ratio		 19.61 15.37 14.06 13.27 9.88 9.86 10.10 9.38 8.72 9.80 10.67
Compound Leverage Factor		 26.82 11.97 11.38 10.55 7.53 8.19 8.60 4.80 7.51 8.81 7.36
Debt to Total Capital		 95.23% 92.13% 91.19% 90.19% 85.10% 83.36% 82.55% 82.36% 78.54% 81.28% 83.24%
Short-Term Debt to Total Capital		 9.65% 16.29% 16.25% 12.43% 10.30% 7.02% 7.04% 3.72% 5.13% 10.75% 13.62%
Long-Term Debt to Total Capital		 85.58% 75.84% 74.94% 77.77% 74.80% 76.34% 75.51% 78.64% 73.41% 70.53% 69.62%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.06% 0.05% 0.06% 0.05% 0.05% 0.05% 0.04% 0.04% 0.04% 0.04% 0.04%
Common Equity to Total Capital		 4.72% 7.82% 8.75% 9.76% 14.85% 16.60% 17.41% 17.61% 21.42% 18.68% 16.72%
Debt to EBITDA		 4.71 4.07 4.08 4.14 3.57 3.27 2.89 3.18 2.64 2.76 2.98
Net Debt to EBITDA		 4.30 3.63 3.30 3.12 2.78 2.54 2.46 2.82 2.24 2.28 2.56
Long-Term Debt to EBITDA		 4.23 3.35 3.35 3.57 3.14 3.00 2.65 3.04 2.47 2.40 2.49
Debt to NOPAT		 6.37 7.21 7.60 7.26 5.97 4.95 4.22 4.56 3.97 4.34 4.67
Net Debt to NOPAT		 5.82 6.44 6.16 5.46 4.65 3.84 3.59 4.05 3.38 3.58 4.01
Long-Term Debt to NOPAT		 5.73 5.94 6.25 6.26 5.25 4.53 3.86 4.36 3.71 3.76 3.90
Altman Z-Score		 1.59 1.78 1.68 1.72 1.65 1.67 1.59 1.78 1.84 1.60 1.59
Noncontrolling Interest Sharing Ratio		 0.55% 0.41% 0.38% 0.32% 0.25% 0.24% 0.24% 0.20% 0.19% 0.20% 0.22%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.66 0.65 0.81 0.94 0.87 0.96 0.89 0.96 0.96 0.93 0.84
Quick Ratio		 0.43 0.44 0.59 0.72 0.63 0.71 0.63 0.66 0.69 0.69 0.61
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -9,055 -7,413 3,391 6,930 16,598 16,289 16,061 14,943 15,512 12,392 11,036
Operating Cash Flow to CapEx		 2,421.99% 2,187.55% 942.32% 2,093.26% 2,318.54% 3,458.45% 3,550.00% 2,396.00% 3,487.32% 4,294.92% 3,500.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.42 0.40 0.40 0.38 0.40 0.40 0.40 0.41 0.41 0.40 0.39
Accounts Receivable Turnover		 5.10 4.85 4.74 4.65 4.85 4.98 4.93 5.11 5.47 5.78 5.42
Inventory Turnover		 4.08 4.71 5.37 5.28 5.52 5.41 4.79 4.93 5.40 5.69 5.06
Fixed Asset Turnover		 11.13 11.02 11.04 10.98 10.95 11.22 11.32 11.34 11.56 11.54 11.33
Accounts Payable Turnover		 0.54 0.66 0.79 0.76 0.76 0.73 0.72 0.76 0.75 0.79 0.79
Days Sales Outstanding (DSO)		 71.51 75.20 77.03 78.57 75.29 73.33 74.04 71.42 66.74 63.20 67.31
Days Inventory Outstanding (DIO)		 89.39 77.42 67.97 69.16 66.12 67.50 76.18 73.97 67.58 64.13 72.12
Days Payable Outstanding (DPO)		 675.79 552.32 463.07 480.46 482.68 501.67 506.87 478.83 484.70 464.27 460.75
Cash Conversion Cycle (CCC)		 -514.89 -399.70 -318.07 -332.72 -341.27 -360.84 -356.66 -333.43 -350.37 -336.94 -321.32
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 64,674 69,598 64,026 63,674 56,662 59,310 64,859 68,417 71,088 73,519 77,415
Invested Capital Turnover		 0.93 0.86 0.85 0.82 0.85 0.83 0.79 0.75 0.76 0.74 0.70
Increase / (Decrease) in Invested Capital		 8,012 10,288 -833 -4,743 -14,426 -14,209 -12,556 -13,539 -10,925 -8,258 -8,451
Enterprise Value (EV)		 372,436 409,620 357,373 371,297 307,792 298,520 278,344 321,218 316,377 277,087 310,864
Market Capitalization		 311,087 346,054 300,125 315,630 261,490 251,304 226,351 266,075 262,543 219,562 248,102
Book Value per Share		 $1.88 $3.42 $3.84 $4.53 $5.87 $6.85 $7.29 $7.50 $9.76 $9.05 $8.29
Tangible Book Value per Share		 ($51.89) ($54.30) ($49.18) ($49.54) ($43.92) ($44.53) ($46.60) ($47.36) ($46.56) ($47.77) ($50.48)
Total Capital		 70,508 77,150 77,455 82,048 69,782 72,875 73,913 75,396 80,558 85,633 87,620
Total Debt		 67,144 71,079 70,634 74,001 59,385 60,746 61,015 62,093 63,271 69,606 72,932
Total Long-Term Debt		 60,340 58,509 58,048 63,805 52,194 55,631 55,812 59,292 59,135 60,399 61,002
Net Debt		 61,310 63,527 57,205 55,627 46,265 47,181 51,961 55,114 53,801 57,492 62,727
Capital Expenditures (CapEx)		 291 249 241 193 205 219 178 175 213 177 143
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11,918 -9,992 -8,670 -10,524 -10,464 -9,724 -6,950 -5,023 -6,168 -5,020 -3,404
Debt-free Net Working Capital (DFNWC)		 -6,363 -2,707 4,487 7,545 2,352 3,566 1,816 1,699 3,061 6,859 6,557
Net Working Capital (NWC)		 -13,167 -15,277 -8,099 -2,651 -4,839 -1,549 -3,387 -1,102 -1,075 -2,348 -5,373
Net Nonoperating Expense (NNE)		 -1,020 1,311 1,185 815 1,348 299 1,478 1,163 2,115 182 1,657
Net Nonoperating Obligations (NNO)		 61,310 63,527 57,205 55,627 46,265 47,181 51,961 55,114 53,801 57,492 62,727
Total Depreciation and Amortization (D&A)		 2,102 2,079 2,131 2,074 2,076 2,235 2,260 2,127 2,157 2,205 2,052
Debt-free, Cash-free Net Working Capital to Revenue		 -21.16% -17.99% -15.76% -19.34% -19.26% -17.64% -12.41% -8.85% -10.62% -8.68% -5.94%
Debt-free Net Working Capital to Revenue		 -11.30% -4.87% 8.16% 13.87% 4.33% 6.47% 3.24% 2.99% 5.27% 11.86% 11.43%
Net Working Capital to Revenue		 -23.37% -27.51% -14.73% -4.87% -8.91% -2.81% -6.05% -1.94% -1.85% -4.06% -9.37%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.02) $0.88 $0.77 $0.77 $0.46 $1.00 $1.14 $0.13 $1.39 $2.22 $0.52
Adjusted Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Diluted Earnings per Share		 ($0.03) $0.88 $0.77 $0.77 $0.45 $1.00 $1.14 $0.13 $1.40 $2.21 $0.51
Adjusted Weighted Average Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.78B 1.78B 1.78B 1.78B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.76B 1.77B 1.77B 1.77B
Normalized Net Operating Profit after Tax (NOPAT)		 -1,043 2,875 2,558 2,187 2,172 2,080 3,505 1,404 4,587 4,134 2,585
Normalized NOPAT Margin		 -6.91% 19.88% 17.69% 17.77% 15.19% 14.94% 25.28% 11.49% 30.34% 27.91% 17.72%
Pre Tax Income Margin		 -15.02% 14.41% 14.84% 14.26% 8.47% 14.02% 18.82% 3.89% 19.61% 29.71% 8.11%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 257.23% 212.33% 201.40% 177.38% 216.27% 159.78% 118.45% 134.04% 84.79% 73.42% 76.40%
Augmented Payout Ratio		 299.39% 239.43% 227.16% 200.35% 257.52% 190.03% 141.15% 160.02% 97.34% 85.44% 89.18%

Frequently Asked Questions About AbbVie's Financials

When does AbbVie's financial year end?

According to the most recent income statement we have on file, AbbVie's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has AbbVie's net income changed over the last 9 years?

AbbVie's net income appears to be on an upward trend, with a most recent value of $4.29 billion in 2024, falling from $5.14 billion in 2015. The previous period was $4.87 billion in 2023. View AbbVie's forecast to see where analysts expect AbbVie to go next.

What is AbbVie's operating income?
AbbVie's total operating income in 2024 was $9.14 billion, based on the following breakdown:
  • Total Gross Profit: $39.43 billion
  • Total Operating Expenses: $30.29 billion
How has AbbVie revenue changed over the last 9 years?

Over the last 9 years, AbbVie's total revenue changed from $22.86 billion in 2015 to $56.33 billion in 2024, a change of 146.4%.

How much debt does AbbVie have?

AbbVie's total liabilities were at $131.80 billion at the end of 2024, a 6.0% increase from 2023, and a 168.4% increase since 2015.

How much cash does AbbVie have?

In the past 9 years, AbbVie's cash and equivalents has ranged from $5.10 billion in 2016 to $39.92 billion in 2019, and is currently $5.52 billion as of their latest financial filing in 2024.

How has AbbVie's book value per share changed over the last 9 years?

Over the last 9 years, AbbVie's book value per share changed from 2.41 in 2015 to 1.88 in 2024, a change of -22.0%.


Related Companies

This page (NYSE:ABBV) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...
Weiss Ratings | Sponsored
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...
Crypto Swap Profits | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored